• GlaxoSmithKline in consumer class action, medical monitoring and product liability litigation alleging an increased risk of cancer.
    • Purdue Pharma in litigation involving prescription opioids.
    • A global automotive supplier in an internal investigation.
    • AbbVie in testosterone replacement therapy product liability litigation.
    • Takata and TK Holdings Inc. in airbag inflator product liability litigation, including dozens of mediations and settlement negotiations.
    • Philip Morris USA in product liability litigation and in consumer fraud class actions.
    • Wyeth and Pfizer in state and federal product liability cases involving hormone therapy medications.
    • Biomet in hip implant product liability litigation.
    • Medtronic in spinal rod implant product liability litigation.
    • Abbott Laboratories in nationwide state court and MDL consumer fraud class action litigation related to a joint venture’s pricing, sales and marketing practices.
    • A European automotive supplier in a US DOJ fraud investigation involving product testing data.
    • A durable medical equipment manufacturer in federal and state criminal and civil investigations, and related consumer fraud class action litigation, focused on the manufacturer’s sales and contracting practices.
    • A pharmaceutical manufacturer in a False Claims Act federal investigation involving allegations of off- label promotion.
    • A consumer products manufacturer in an international internal investigation regarding allegations of tax fraud.
    • A sub-prime lender in an SEC investigation focused on the adequacy of the lender’s reserves and its loss disclosures.
    • The chairman/CEO of a sub-prime lender in an SEC investigation focused on the lender’s loan loss reserves and related disclosures.

    Includes matters handled at Dechert or prior to joining the firm.

     
    • FDA Issues Final Rule Clarifying Evidence of Off-Label Marketing - (August 09, 2021)
    • Drug Cos. May Find Real-World Evidence Cuts Both Ways - (April 15, 2020)
    • COVID-19 Coronavirus Business Impact: How the COVID-19 Pandemic May Impact New Product Liability Litigation and Trends - (April 01, 2020)
    • Running on Empty: A 10-Point Plan for the Aviation and Transportation Industry as It Meets the Challenges and Opportunities Presented by the COVID-19 Coronavirus Crisis - (March 31, 2020)
    • Science Days in Mass Torts - (August 06, 2019)
    • Dechert Detect - (February 06, 2019)
    • When A Compliance Crisis Presents An Opportunity - (April 24, 2018)
    • Self-Driving Uber Fatality Could Complicate Regulations - (April 03, 2018)
    • Plan for Success - Strategies to Win at Mediation - (March 14, 2018)
    • Digital Health Technology: A New Year and New FDA Guidance - (January 19, 2018)
    • Preview of Automated Vehicle Regulations in Germany - (September 07, 2017)
    • DOT Releases New Federal Guidance for Automated Driving Systems - (September 01, 2017)
    • House Committee Passes Self-Driving Vehicle Legislation - (August 24, 2017)
    • Chicago Proposes Pharma Rep Licensing Rules and Ethical Standards - (March 20, 2017)
    • Proposed Rules Pose Challenges For Pharma Reps In Chicago - (March 17, 2017)
    • What’s Next for the FDA’s Draft Social Media Guidances? - (December 08, 2014)
    • Comcast Turns 1: Trends In Class Certification - (March 06, 2014)
    • Public Comments on Proposed Amendments to the Federal Rule of Civil Procedure - (February 14, 2014)
    • Recent Regulatory and Enforcement Actions: What Do They Mean for Your Compliance Efforts? - (April 16, 2013)
    • Mandatory Compliance with "Voluntary" Codes - (October 01, 2008)
    • The FDA’s Medical Reprint Policy - a Cautious Compromise - (August 01, 2008)
    • DRI Drug and Medical Device Seminar — Nashville, TN (September 7-9, 2022)
    • Daubert Revisited: Examining Recent Proposed Amendments to Rule 702 and What They Could Mean for the Future of Drug and Device Litigation — ACI's 26th Annual Drug and Med Litigation Conference, New York, NY (December 7- 8, 2021)
    • DRI Drug and Medical Device Seminar (April 29-30, 2021)
    • DRI Drug and Medical Device Seminar (November 5-6, 2020)
    • DRI Drug and Medical Device Seminar — Washington, D.C. (May 16-17, 2019)
    • DRI Drug and Medical Device Seminar — New York (May 10, 2018)
    • Frye and Daubert Challenges –Motion Strategy and Medical Expert Testimony — Defense Lawyers of Wyoming Annual Meeting, Saratoga, WY (August 10, 2017)
    • Plan for Success: Mediation Strategies for Successfully Resolving Litigation — International Association of Defense Counsel Annual Meeting, Québec City, Québec Canada (July 11, 2017) 
    • Social Media as a Catalyst to Products Liability Litigation? Delineating the Scope of Manufacturers' Duty vis-à-vis Internet Marketing and Presence — ACI's 19th Annual Drug and Med Litigation Conference, New York, NY (December 9, 2014)
    • Gatekeeper or Grim Reaper: Frye and Daubert Challenges –Motion Strategy and Medical Expert Testimony — DRI's 2014 Complex Medicine Seminar, San Diego, CA (November 13, 2014) 
    • Minimizing the Risk of the Sales Force Crossing the Line — Pharmaceutical and Medical Device Company's Guide to Off-Label Communications Conference, Presented by the American Conference Institute, Philadelphia, PA (July 14, 2009)